Heron Therapeutics | HRTX - Ebitda

Aktienkurs
0.78
Täglich Wechseln
-0.04 -4.74%
Monatlich
-34.57%
Jährlich
-67.29%
Q1 Prognose
0.76




Ebitda Veränderung Datum
ALKERMES USD 100.31M 21.24M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amarin USD 12.54M 28.57M 2025-06
ANI Pharmaceuticals USD 65.36M 5.76M 2025-12
Anika Therapeutics USD 4.54M 3.67M 2025-12
Arrowhead Research USD 64.2M 223.53M 2025-09
Eisai JPY 30.1B 6.62B 2025-12
Esperion Therapeutics USD -9.93M 24.99M 2025-09
GlaxoSmithKline GBP 3.36B 179M 2025-09
Heron Therapeutics USD -3.88M 5.63M 2024-09
Insmed USD -314.19M 31.48M 2025-12
Ligand Pharmaceuticals USD 150.32M 129.42M 2025-09
Merck USD 8.39B 1.97B 2025-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Omeros USD -47.96M 7.39M 2023-09
Pacira USD 38.71M 10.65M 2025-12
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Roche Holding CHF 12.68B 2.36B 2024-06
Surmodics USD 1.53M 485K 2024-09
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
Veracyte USD 42.31M 2.58M 2025-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09